To cover vesting taxes, Andrew Toy proposes selling 309,558 Clover Health (CLOV) shares.
Andrew Toy, an officer at Clover Health Investments, Corp. (CLOV), plans to sell 309,558 shares of Class A Common Stock with an aggregate market value of $1,309,430.34. This proposed sale is a "sell-to-cover" transaction intended to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, not a discretionary transaction. The filing also notes previous sales made under a 10b5-1 plan in July and August 2026.
Robert G. Torricelli Files Initial Ownership Disclosure as Clover Health Director
Robert G. Torricelli has filed an initial ownership disclosure for Clover Health Investments, Corp. (NASDAQ:CLOV) following his appointment as a director. The filing indicates he beneficially owns 174,416 shares, comprising 141,253 directly held Class A Common Stock shares and 33,163 shares underlying restricted stock units that vest in April 2027. This disclosure was made public on October 1, 2026, with the triggering event of his directorship occurring on September 22, 2026.
Total common shares outstanding of Clover Health Investments Corp. Class A – HAN:7QD
The article focuses on the total common shares outstanding for Clover Health Investments Corp. Class A, traded under the symbol HAN:7QD on the Hannover Stock Exchange. It provides a static snapshot of this financial metric and indicates that the information is "Made by humans."
Form 8K Clover Health Investments Corp For: 25 September By Investing.com
This article announces that Clover Health Investments Corp. filed a Form 8K on September 25. The publication by Investing.com provides no further details beyond this announcement and includes general market data and news headlines not related to the filing itself.
Form 8K Clover Health Investments Corp For: 25 September By Investing.com
This article announces that Clover Health Investments Corp. filed a Form 8K on September 25. The brief report from Investing.com includes the stock symbol CLOV, which experienced a slight decrease of 0.44%.
Clover Health Investments, Corp. (CLOV) Stock Price, News, Quote & History
This page provides detailed financial information for Clover Health Investments, Corp. (CLOV), including its current stock price, historical data, and key statistics. It presents a summary of the company's market performance, valuation measures, profitability, and balance sheet information, along with recent news and research reports. The page also includes a chart for visualizing stock trends and offers various financial metrics for analysis.
Clover Health (NASDAQ: CLOV) exec plans stock sale to cover taxes
Joseph Frank Oldakowski, an officer at Clover Health Investments, Corp. (CLOV), has filed a notice to sell 3,170 shares of Class A Common Stock. This transaction, executed under Rule 144, is a "sell to cover" to satisfy tax withholding obligations related to vested restricted stock units and is not a discretionary sale. Oldakowski has made previous sales in the last three months, including 12,102 shares and 20,000 shares on separate occasions.
Clover Health (CLOV) officer plans tax-withholding share sale
An officer at Clover Health (CLOV), Karen M. Soares, has filed a Form 144 indicating her intent to sell 6,416 shares of Class A common stock on September 15, 2026. This "sell to cover" transaction is primarily to satisfy tax withholding obligations arising from the vesting of restricted stock units. The proposed sale, valued at $29,898.56, is not considered a discretionary trade but rather a routine transaction for tax purposes.
Clover Health (CLOV) exec sells 1,921 shares under preset plan
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 1,921 shares of Class A Common Stock on September 17, 2026, for $4.56 per share, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Reynoso still directly holds 2,803,446 shares of CLOV. The sale, valued at approximately $9,000, was reported in a Form 4 SEC filing.
Clover Health (NASDAQ: CLOV) exec sale is tax-driven
Clover Health's VP of Finance and Controller, Joseph Frank Oldakowski, sold 3,170 shares of Class A Common Stock at $4.64 per share on September 16, 2026. This transaction was not a discretionary trade but a mandatory "sell to cover" to satisfy tax withholding obligations from the vesting of restricted stock units (RSUs). After the sale, Oldakowski directly holds 275,897 shares, and the remaining RSUs will vest quarterly until June 2029.
Clover Health (NASDAQ: CLOV) Medicare chief sells 9,273 shares to cover RSU taxes
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 9,273 Class A shares at a weighted average price of $4.78 per share on September 15, 2026. This sale was a mandatory "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Reynoso directly holds 2,805,367 shares of Class A Common Stock.
Clover Health (CLOV) insider sells 300,000 shares in pre-set plan
Clover Health officer Wai Conrad sold 300,000 Class A shares for approximately $1.42 million under a pre-set Rule 10b5-1 plan. The sale occurred on September 15, 2026, at a weighted average price of $4.72 per share. Following the transaction, Conrad continues to hold over 2.2 million shares, both directly and through a family trust.
Clover Health CEO, Medicare advantage, Jamie Reynoso sells $44,324 in CLOV shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 9,273 shares of the company's Class A Common Stock for $44,324 on September 15, 2026, to cover tax withholding obligations from vested restricted stock units. This sale occurred after Clover Health's stock surged 137% in six months and despite the stock currently being considered overvalued by InvestingPro. The company recently exceeded Q2 2026 earnings and revenue expectations, and raised its full-year outlook.
Clover Health CFO Karen Soares sells $32,723 in stock
Clover Health CFO Karen Soares sold 6,846 shares of Class A Common Stock for $32,723 on September 15, 2026. This "sell to cover" transaction was to meet tax withholding obligations related to the vesting of restricted stock units. The sale occurred amidst a 137% surge in Clover Health shares over six months and a recent strong Q2 2026 earnings report that exceeded analyst expectations.
Clover Health CFO Karen Soares sells $32,723 in stock By Investing.com
Clover Health CFO Karen Soares sold 6,846 shares of Class A Common Stock for $32,723 on September 15, 2026, to cover tax withholding obligations from vested restricted stock units. This "sell to cover" transaction is not a discretionary trade. The sale occurred as Clover Health's shares have surged, and the company recently exceeded Q2 2026 earnings and revenue expectations.
Clover Health (CLOV) investor plans tax sell-to-cover trade
A Clover Health (CLOV) stockholder, Jamie Reynoso, plans to sell 8,691 shares of Class A common stock valued at $40,500.06 through Morgan Stanley Smith Barney LLC. This sale is a "sell to cover" transaction to fulfill tax withholding obligations upon the vesting of restricted stock units, not a voluntary reduction in investment. The filing also notes previous 10b5-1 plan sales by Reynoso in the past three months.
Clover Health to Participate in Upcoming Investor Conferences
Clover Health Investments, Corp. announced its participation in two upcoming investor conferences in September 2026. Interim Chief Financial Officer, Clay Thornton, will present at the Jefferies Healthcare Services and Technology Conference and also participate in the Deutsche Bank Healthcare Summit. The company is a physician enablement technology firm focused on improving healthcare access and outcomes for Medicare beneficiaries through its Clover Assistant platform.
Clover Health interim CFO Thornton sells $78,032 in shares By Investing.com
Joseph Clay Thornton, interim CFO of Clover Health Investments Corp., sold 17,775 shares valued at $78,032. These sales were not discretionary but were "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units (RSUs). The company has recently reported strong Q2 2026 financial results, exceeding Wall Street expectations, and raised its full-year outlook.
Clover Health (NASDAQ: CLOV) CFO’s tax sale covers RSU vesting
Clover Health's Interim CFO, Joseph Clay, sold 17,775 shares of Class A Common Stock at a weighted average price of $4.39 per share on August 17, 2026. This transaction was a non-discretionary "sell to cover" to satisfy tax obligations related to the vesting of 6.25% of his restricted stock units (RSUs). After the sale, Clay directly holds 1,249,526 shares, and his remaining RSUs will continue to vest quarterly through February 2028.
Clover Health interim CFO Thornton sells $78,032 in shares
Joseph Clay Thornton, interim CFO of Clover Health Investments, sold 17,775 shares of the company's Class A Common Stock for $78,032. These sales were not discretionary but rather "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units (RSUs). Following the transactions, Thornton beneficially owns 1,249,526 shares.
Clover Health (NASDAQ: CLOV) notes $21K 10b5-1 sale by Thornton
Clover Health Investments Corp. (NASDAQ: CLOV) filed a Form 144, indicating a planned transaction involving 16,942 Class A shares linked to restricted stock units granted on August 16, 2026. The filing also disclosed a prior 10b5-1 Plan Sale by Joseph Clay Thornton on July 15, 2026, where 4,630 Class A shares were sold for $21,622.10. The shares for the planned transaction are held through Morgan Stanley Smith Barney LLC.
Clover Health Interim CFO Joseph Clay Thornton Awarded 54,347 RSUs with Four-Year Vesting
Clover Health's Interim CFO, Joseph Clay Thornton, was granted 54,347 Restricted Stock Units (RSUs) of Class A Common Stock. These RSUs, valued at $0, will vest over a four-year period, with 25% vesting on August 12, 2027, and the remainder in quarterly installments, fully vesting by August 12, 2030. This grant increases Thornton's direct beneficial ownership to 1,267,301 shares of Class A Common Stock, contingent upon his continued service.
Clover Health CEO Andrew Toy sells $408,260 in stock By Investing.com
Clover Health CEO Andrew Toy sold 87,798 shares of the company's Class A Common Stock for approximately $408,260. This "sell to cover" transaction was not discretionary but mandated to fulfill tax withholding obligations tied to previously granted restricted stock units. Following this, Mr. Toy beneficially owns over 9.4 million shares.
Clover Health CEO Andrew Toy sells $408,260 in stock
Clover Health CEO Andrew Toy sold 87,798 shares of Class A Common Stock for approximately $408,260. These shares were sold to cover tax withholding obligations from vested restricted stock units, not as discretionary trades. Following the sale, Toy still beneficially owns over 9.4 million shares of Clover Health.
CLOV (Nasdaq: CLOV) discloses planned 85,704-share sale by Andrew Toy
Clover Health Investments, Corp. (Nasdaq: CLOV) has disclosed a planned sale of 85,704 shares of Class A common stock by Andrew Toy through Morgan Stanley Smith Barney LLC, valued at approximately $391,667.28. These shares originate from Restricted Stock Units acquired as compensation on August 8, 2026, with the sale targeting around August 10, 2026. The filing also details previous Rule 10b5-1 plan sales by Andrew Toy on July 1 and July 15, 2026.
Clover Health (CLOV) CEO Andrew Toy sells 87,798 shares for tax withholding
Clover Health CEO Andrew Toy sold 87,798 shares of Class A Common Stock for $408K on August 10, 2026, at a weighted average price of $4.65 per share. This sale was non-discretionary and conducted solely to cover tax withholding obligations associated with the final vesting of restricted stock units. Following this transaction, Toy directly holds 9,459,316 shares of Class A Common Stock.
Clover Health Investments Corp. Class A Revenue Breakdown – MUN:7QD
Clover Health Investments Corp. (MUN:7QD) generated €1.64 billion in revenue last year, primarily from its Insurance segment. All of this revenue, €1.64 billion, originated from the United States, indicating the company's strong focus on the US market in the life and health insurance sector.
Clover Health Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach involving Clover Health Investments, Corp. dba Clover Health. The breach, which was detected on July 8, 2020, and disclosed to the SEC on July 4, 2026, exposed sensitive personally identifiable and protected health information. Individuals affected by the breach may be entitled to compensation and are encouraged to submit a claim for review.
Clover Health Investments Corp. Class A Revenue Breakdown – LS:A2QJXX
Clover Health Investments Corp. Class A (A2QJXX) generated 1.64 billion EUR in revenue last year, primarily from its Insurance segment. This represents an increase from 1.32 billion EUR in the previous year. The entire revenue was generated in the United States.
Clover Health CEO Jamie Reynoso sells $21,920 in CLOV stock By Investing.com
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 4,839 shares of CLOV stock for $21,920, at a weighted average price of $4.53 per share, according to a Rule 10b5-1 trading plan. This transaction occurred after Clover Health shares surged 73% in six months, and the company recently reported mixed Q1 2026 earnings but had its Medicare star rating upgraded to 4.5 stars. Despite the stock appearing slightly overvalued, Reynoso still holds over 2.8 million shares.
Clover Health CEO, Medicare Advantage Jamie L. Reynoso disposes of 4,839 shares for $21,920.67
Jamie L. Reynoso, CEO of Clover Health Medicare Advantage, sold 4,839 Class A common shares on July 17, 2026, for a total of $21,920.67 at a price of $4.53 per share. Following this transaction, Reynoso's direct stake in Clover Health fell to 2.81 million shares. This information was generated by AI from an original filing by Clover Health Investments Corp. with the SEC.
Clover Health Investments (CLOV) insider sells 4,839 shares under 10b5-1
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), sold 4,839 shares of Class A Common Stock on July 17, 2026. The shares were sold at a weighted average price of $4.53 per share, ranging from $4.35 to $4.63, as part of a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following this transaction, Reynoso directly holds 2,814,640 shares of CLOV.
Clover Health (CLOV) interim CFO sells 4,630 shares to cover taxes
Clover Health's interim CFO, Joseph Clay, sold 4,630 shares of Class A Common Stock on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations related to the vesting of 6.25% of his restricted stock units. Following this transaction, Clay directly holds 1,212,954 shares.
Clover Health CEO Andrew Toy sells $292,860 in shares
Clover Health CEO Andrew Toy sold 62,711 shares of Class A Common Stock for approximately $292,860 on July 15, 2026. This sale was non-discretionary, made to cover tax withholding obligations associated with the vesting of restricted stock units. Despite the sale, Toy still directly owns over 9.5 million shares, and the company is predicted to become profitable this year after a significant Medicare star rating upgrade.
Clover Health: Counterpart Health CEO Wai sells $113,084 in stock.
Conrad Wai, CEO of Counterpart Health at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 24,215 shares of the company’s Class A Common Stock for $113,084. This sale was a "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units and not a discretionary trade. The company recently reported mixed Q1 2026 earnings but received a Medicare star rating upgrade to 4.5 stars.
Clover Health (CLOV) CEO sells 62,711 shares for RSU tax withholding
Clover Health Investments CEO Andrew Toy sold 62,711 Class A shares at a weighted average price of $4.67 per share. This mandatory "sell to cover" transaction was executed to fulfill tax withholding obligations tied to the vesting of 6.25% of his restricted stock units (RSUs), which were originally granted on October 15, 2024. After this non-discretionary sale, Toy directly holds 9,547,114 shares, with remaining RSUs vesting quarterly until October 15, 2028.
Clover Health Investments (CLOV) legal chief sells shares in tax-cover transaction
Clover Health Investments' Chief Legal Officer, Karen Soares, sold 10,519 shares of Class A common stock at a weighted average price of $4.67 per share on July 15, 2026. This transaction was to cover tax withholding obligations from the vesting of restricted stock units and was not a discretionary trade. After the sale, Soares retains 1,557,222 shares, with remaining RSUs vesting quarterly until October 2028.
Clover Health (CLOV) exec sells 13,119 shares to cover RSU tax withholding
Clover Health Investments, Corp. executive Jamie L. Reynoso sold 13,119 shares of Class A Common Stock on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units (RSUs), not a discretionary trade. Following this transaction, Reynoso's direct holdings amount to 2,819,479 shares.
Clover Health (NASDAQ: CLOV) insider sale covers RSU tax obligations
Clover Health insider Wai Conrad sold 24,215 Class A shares on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations from the vesting of 6.25% of his restricted stock units (RSUs). Following the sale, Conrad holds 1,145,699 direct shares and 1,390,056 indirect shares, with remaining RSUs vesting quarterly until October 2028.
CLOV (Nasdaq: CLOV) plans Rule 144 sale of 60765 shares
Clover Health Investments, Corp. (Nasdaq: CLOV) has filed a Form 144 notice for the planned sale of 60,765 shares of Class A Common Stock. These shares originate from Restricted Stock Units granted as compensation and are scheduled to be sold on Nasdaq via Morgan Stanley Smith Barney LLC on July 15, 2026. The filing also discloses Andrew Toy's prior 10b5-1 sales of 313,476 Class A shares on July 1, 2026, for total proceeds of $1,667,692.32.
Sale of 12,712 shares planned in CLOV (Nasdaq: CLOV) notice
An affiliate of Clover Health Investments (Nasdaq: CLOV) plans to sell 12,712 Class A common shares, valued at $59,492.16, through Morgan Stanley Smith Barney LLC around July 15, 2026. These shares originated from restricted stock units granted as compensation. The filing also notes previous 10b5-1 sales by Jamie Reynoso in June and July 2026.
CLOV (CLOV) plans sale of 23,463 Class A common shares
Clover Health Investments, Corp. (CLOV) has filed a Form 144 disclosing a planned sale of 23,463 shares of Class A Common Stock with an aggregate market value of $109,806.84 through Morgan Stanley Smith Barney LLC on July 15, 2026. These shares originated from restricted stock units granted as compensation. Over the prior three months, 220,426 Class A shares were sold for $879,499.74 under 10b5-1 Plan Sales for Conrad Wai.
Weekly Recap: Clover Q2 webcast and Counterpart CA ups discharge data, meds
Clover Health (NASDAQ:CLOV) is scheduled to release its Q2 2026 results on August 5, 2026, followed by a webcast. Its unit, Counterpart Health, reported significant improvements for Clover Medicare Advantage members, with CA-enabled PCPs facilitating 33% more hospital discharge information and 11% better post-discharge medication reconciliation.
Clover Health Medicare Advantage CEO sells $11,157 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 2,384 shares of the company's Class A Common Stock for a total of $11,157 on July 8, 2026. This transaction was part of a pre-arranged trading plan. Following the sale, Reynoso still holds over 2.8 million shares, and the company's stock has seen significant year-to-date and six-month gains despite a recent weekly decline.
Clover Health (CLOV) Medicare Advantage CEO sells small stake under Rule 10b5-1 plan
Clover Health Investments, Corp. CEO of Medicare Advantage, Jamie L. Reynoso, sold 2,384 shares of Class A Common Stock at $4.68 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, and leaves Reynoso with 2,832,598 shares directly held. The sale amounts to $11,157 and is considered a neutral filing impact with negative sentiment due to it being a sell.
Jamie Reynoso 10b5-1 sales listed in CLOV Form 144 (CLOV)
A recently filed Form 144 for Clover Health Investments, Corp. (CLOV) details multiple 10b5-1 sales by Jamie Reynoso. The filing, dated July 6, 2026, lists sales on March 18, 2026, June 11, 2026, June 15, 2026, and June 17, 2026, along with Restricted Stock Units dated July 3, 2026. This SEC document provides transparency regarding insider stock transactions under a pre-arranged trading plan.
Clover Health (CLOV) exec sells 6,229 shares in mandated tax-withholding trade
Jamie L. Reynoso, CEO of Medicare Advantage for Clover Health (CLOV), sold 6,229 shares of Class A Common Stock at $5.26 per share. This transaction was not a discretionary trade but a "sell to cover" action to meet tax withholding obligations related to the vesting of restricted stock units (RSUs). After the sale, Reynoso still directly holds 2,834,982 shares of the company.
Clover Health Medicare Advantage CEO Reynoso sells $32,764 in stock
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold 6,229 shares of Class A Common Stock for $32,764 on July 6, 2026. This sale was a "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units. Clover Health recently reported mixed Q1 2026 earnings and had its Medicare star rating upgraded to 4.5 Stars following a lawsuit victory.
Clover Health (CLOV) CEO’s 313,476-share sale tied to RSU tax withholding
Clover Health Investments, Corp. (CLOV) CEO Andrew Toy sold 313,476 shares of Class A common stock at $5.32 per share. This sale was explicitly to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and was a non-discretionary "sell to cover" transaction, as mandated by the company's equity incentive plans. Following the sale, Toy directly holds 9,609,825 shares, and the remaining RSUs will continue to vest quarterly through January 1, 2027.
Clover Health CEO Andrew Toy sells $1.67 million in stock By Investing.com
Clover Health CEO Andrew Toy sold 313,476 shares of Class A Common Stock for $1.67 million to cover tax withholding obligations related to vested restricted stock units. This sale was a "sell to cover" transaction and not a discretionary trade. The stock, trading near its 52-week high, appears overvalued according to InvestingPro analysis, despite a recent Medicare star rating upgrade and exceeding revenue expectations in Q1 2026.
